Utah Medical Products, Inc. (NASDAQ: UTMD) Stock Competitors & Peer Comparison
See UTMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UTMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTMD | $67.14 | +4.61% | 213.8M | 19.86 | $3.38 | +1.86% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
UTMD vs BDX Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BDX's P/E ratio is 11.62. In terms of profitability, UTMD's ROE is +0.09%, compared to BDX's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
UTMD vs BDXA Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BDXA's P/E ratio is 45.70. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
UTMD vs MDLN Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas MDLN's P/E ratio is 45.06. In terms of profitability, UTMD's ROE is +0.09%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, UTMD is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
UTMD vs WST Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas WST's P/E ratio is 41.19. In terms of profitability, UTMD's ROE is +0.09%, compared to WST's ROE of +0.19%. Regarding short-term risk, UTMD is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
UTMD vs HOLX Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas HOLX's P/E ratio is 31.54. In terms of profitability, UTMD's ROE is +0.09%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, UTMD is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
UTMD vs COO Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas COO's P/E ratio is 15.42. In terms of profitability, UTMD's ROE is +0.09%, compared to COO's ROE of +0.03%. Regarding short-term risk, UTMD is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
UTMD vs BDXB Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BDXB's P/E ratio is 7.60. In terms of profitability, UTMD's ROE is +0.09%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, UTMD is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
UTMD vs BAX Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BAX's P/E ratio is 10.77. In terms of profitability, UTMD's ROE is +0.09%, compared to BAX's ROE of -0.16%. Regarding short-term risk, UTMD is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
UTMD vs ATR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ATR's P/E ratio is 23.13. In terms of profitability, UTMD's ROE is +0.09%, compared to ATR's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
UTMD vs AVTR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas AVTR's P/E ratio is 13.46. In terms of profitability, UTMD's ROE is +0.09%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, UTMD is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
UTMD vs RGEN Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas RGEN's P/E ratio is 73.31. In terms of profitability, UTMD's ROE is +0.09%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, UTMD is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
UTMD vs TFX Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas TFX's P/E ratio is 12.32. In terms of profitability, UTMD's ROE is +0.09%, compared to TFX's ROE of -0.28%. Regarding short-term risk, UTMD is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
UTMD vs BLCO Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BLCO's P/E ratio is 24.88. In terms of profitability, UTMD's ROE is +0.09%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, UTMD is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
UTMD vs STVN Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas STVN's P/E ratio is 31.81. In terms of profitability, UTMD's ROE is +0.09%, compared to STVN's ROE of +0.10%. Regarding short-term risk, UTMD is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
UTMD vs MMSI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas MMSI's P/E ratio is 19.01. In terms of profitability, UTMD's ROE is +0.09%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, UTMD is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
UTMD vs ICUI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ICUI's P/E ratio is 19.66. In terms of profitability, UTMD's ROE is +0.09%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, UTMD is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
UTMD vs HAE Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas HAE's P/E ratio is 15.86. In terms of profitability, UTMD's ROE is +0.09%, compared to HAE's ROE of +0.11%. Regarding short-term risk, UTMD is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
UTMD vs XRAY Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas XRAY's P/E ratio is 9.04. In terms of profitability, UTMD's ROE is +0.09%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, UTMD is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
UTMD vs LMAT Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas LMAT's P/E ratio is 37.05. In terms of profitability, UTMD's ROE is +0.09%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, UTMD is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
UTMD vs PLSE Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas PLSE's P/E ratio is -27.48. In terms of profitability, UTMD's ROE is +0.09%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, UTMD is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
UTMD vs ATRC Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, UTMD is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
UTMD vs BLFS Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas BLFS's P/E ratio is -141.85. In terms of profitability, UTMD's ROE is +0.09%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, UTMD is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
UTMD vs AZTA Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas AZTA's P/E ratio is 60.82. In terms of profitability, UTMD's ROE is +0.09%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, UTMD is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
UTMD vs KMTS Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas KMTS's P/E ratio is -8.92. In terms of profitability, UTMD's ROE is +0.09%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, UTMD is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
UTMD vs STAA Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas STAA's P/E ratio is 41.02. In terms of profitability, UTMD's ROE is +0.09%, compared to STAA's ROE of -0.06%. Regarding short-term risk, UTMD is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
UTMD vs QDEL Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas QDEL's P/E ratio is 11.98. In terms of profitability, UTMD's ROE is +0.09%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, UTMD is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
UTMD vs ATRI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ATRI's P/E ratio is 64.50. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, UTMD is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
UTMD vs ANGO Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ANGO's P/E ratio is -34.85. In terms of profitability, UTMD's ROE is +0.09%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, UTMD is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
UTMD vs NNNN Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas NNNN's P/E ratio is 145.38. In terms of profitability, UTMD's ROE is +0.09%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, UTMD is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
UTMD vs OSUR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas OSUR's P/E ratio is -4.78. In terms of profitability, UTMD's ROE is +0.09%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, UTMD is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
UTMD vs SMTI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas SMTI's P/E ratio is -426.00. In terms of profitability, UTMD's ROE is +0.09%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, UTMD is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check SMTI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
UTMD vs INFU Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas INFU's P/E ratio is 23.97. In terms of profitability, UTMD's ROE is +0.09%, compared to INFU's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
UTMD vs KRMD Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas KRMD's P/E ratio is -95.75. In terms of profitability, UTMD's ROE is +0.09%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, UTMD is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
UTMD vs PDEX Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas PDEX's P/E ratio is 19.34. In terms of profitability, UTMD's ROE is +0.09%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, UTMD is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
UTMD vs MBOT Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas MBOT's P/E ratio is -6.58. In terms of profitability, UTMD's ROE is +0.09%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, UTMD is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
UTMD vs AKYA Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas AKYA's P/E ratio is -1.34. In terms of profitability, UTMD's ROE is +0.09%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, UTMD is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
UTMD vs STSS Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas STSS's P/E ratio is -0.02. In terms of profitability, UTMD's ROE is +0.09%, compared to STSS's ROE of -1.66%. Regarding short-term risk, UTMD is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
UTMD vs DXR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas DXR's P/E ratio is 27.33. In terms of profitability, UTMD's ROE is +0.09%, compared to DXR's ROE of +0.22%. Regarding short-term risk, UTMD is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
UTMD vs OMIC Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas OMIC's P/E ratio is -0.58. In terms of profitability, UTMD's ROE is +0.09%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, UTMD is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
UTMD vs IGAP Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas IGAP's P/E ratio is -10.52. In terms of profitability, UTMD's ROE is +0.09%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, UTMD is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
UTMD vs NEPH Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas NEPH's P/E ratio is 50.86. In terms of profitability, UTMD's ROE is +0.09%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, UTMD is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
UTMD vs MLSS Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas MLSS's P/E ratio is -6.50. In terms of profitability, UTMD's ROE is +0.09%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, UTMD is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
UTMD vs POCI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas POCI's P/E ratio is -6.07. In terms of profitability, UTMD's ROE is +0.09%, compared to POCI's ROE of -0.37%. Regarding short-term risk, UTMD is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
UTMD vs SDC Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas SDC's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to SDC's ROE of -1.96%. Regarding short-term risk, UTMD is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
UTMD vs HBIO Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas HBIO's P/E ratio is -16.81. In terms of profitability, UTMD's ROE is +0.09%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, UTMD is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
UTMD vs IVC Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas IVC's P/E ratio is -0.79. In terms of profitability, UTMD's ROE is +0.09%, compared to IVC's ROE of -0.46%. Regarding short-term risk, UTMD is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
UTMD vs RVP Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas RVP's P/E ratio is -2.06. In terms of profitability, UTMD's ROE is +0.09%, compared to RVP's ROE of -0.08%. Regarding short-term risk, UTMD is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
UTMD vs ZJYL Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, UTMD's ROE is +0.09%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, UTMD is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
UTMD vs FEMY Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas FEMY's P/E ratio is -10.25. In terms of profitability, UTMD's ROE is +0.09%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, UTMD is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
UTMD vs RGNT Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas RGNT's P/E ratio is -0.08. In terms of profitability, UTMD's ROE is +0.09%, compared to RGNT's ROE of N/A. Regarding short-term risk, UTMD is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
UTMD vs NSTG Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas NSTG's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, UTMD is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
UTMD vs NXGL Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas NXGL's P/E ratio is -1.13. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, UTMD is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
UTMD vs POAI Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas POAI's P/E ratio is -0.03. In terms of profitability, UTMD's ROE is +0.09%, compared to POAI's ROE of -107.05%. Regarding short-term risk, UTMD is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
UTMD vs LUCY Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas LUCY's P/E ratio is -0.39. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, UTMD is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
UTMD vs MHUA Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas MHUA's P/E ratio is 0.25. In terms of profitability, UTMD's ROE is +0.09%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, UTMD is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
UTMD vs NXGLW Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, UTMD's ROE is +0.09%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, UTMD is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
UTMD vs GMVD Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas GMVD's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
UTMD vs GMVDW Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas GMVDW's P/E ratio is N/A. In terms of profitability, UTMD's ROE is +0.09%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, UTMD is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
UTMD vs AVGR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas AVGR's P/E ratio is -0.05. In terms of profitability, UTMD's ROE is +0.09%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, UTMD is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
UTMD vs LUCYW Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, UTMD's ROE is +0.09%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, UTMD is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
UTMD vs GCTK Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas GCTK's P/E ratio is -0.01. In terms of profitability, UTMD's ROE is +0.09%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, UTMD is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for UTMD.Check GCTK's competition here
IntriCon Corporation (NASDAQ: IIN)
UTMD vs IIN Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, IIN has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas IIN's P/E ratio is 226.45. In terms of profitability, UTMD's ROE is +0.09%, compared to IIN's ROE of -0.00%. Regarding short-term risk, UTMD is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
UTMD vs APR Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, APR has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas APR's P/E ratio is 22.59. In terms of profitability, UTMD's ROE is +0.09%, compared to APR's ROE of +9.81%. Regarding short-term risk, UTMD is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
UTMD vs ATRS Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ATRS's P/E ratio is 14.95. In terms of profitability, UTMD's ROE is +0.09%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, UTMD is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
UTMD vs HRC Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, HRC has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas HRC's P/E ratio is 41.92. In terms of profitability, UTMD's ROE is +0.09%, compared to HRC's ROE of +0.14%. Regarding short-term risk, UTMD is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
UTMD vs ALOG Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas ALOG's P/E ratio is 40.93. In terms of profitability, UTMD's ROE is +0.09%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, UTMD is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
UTMD vs IVTY Comparison July 2026
Utah Medical Products, Inc. (NASDAQ: UTMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTMD stands at 213.8M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, UTMD is priced at $67.14 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTMD currently has a P/E ratio of 19.86, whereas IVTY's P/E ratio is -3.80. In terms of profitability, UTMD's ROE is +0.09%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, UTMD is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for UTMD.Check IVTY's competition here